BOARD-ADVISORS-AG
3.11.2021 11:22:10 CET | Business Wire | Press release
LEA Partners GmbH (LEA), a private equity and venture capital investor based in Karlsruhe, Germany, today announced the acquisition of Base-Net Informatik AG (Base-Net), a Swiss software provider leading in the field of credit and mortgage management.
Board Advisors Deutschland AG acted as the exclusive M&A advisor to the shareholders of Base-Net. The team of Christoph Löslein, Urs Niederberger, Felix Brokatzky and Federico Arcelli was able to successfully complete the transaction in less than five months.
"I am extremely pleased that, through the efforts of Board Advisors, we were able to find a new majority shareholder that is equally beneficial to the customers and employees of Base-Net Informatik AG. Despite a complex transaction structure, the advisors of Board Advisors had the mandate under control at all times, were able to successfully complete the project in a record-breaking time and to the full satisfaction of the shareholders."
Stefan Hermann, Founder and Chairman of the Board of Base-Net Informatik AG
Base-Net, headquartered in Sursee in the canton of Lucerne, was founded in 1994. With its WinCredit software it is the leading Swiss software provider in the field of credit and mortgage management. Currently, over 400 banks, insurance companies, pension funds and financial intermediaries use the company's software. In addition, Base-Net develops and operates a state-of-the-art platform for credit and mortgage refinancing.
"The market for credit management software is continuously growing and is highly attractive for us. Therefore, we are very pleased to have gained Base-Net, another leading and long-established company, for us. With this, we are taking another step in building a leading financial services platform in the DACH region."
Philipp Hertel, Partner at LEA
About Base-Net
Base-Net is the leading Swiss software provider in the field of credit and mortgage management. In addition to its loan management software, its solutions for refinancing and exchanges with the Swiss Pfandbriefbank are among the standard solutions in the Swiss financial sector. Founded in 1994 and based in Sursee, the company now serves around 400 banks and insurance companies. For more information, please visit www.basenet.ch .
About LEA Partners
LEA Partners is an entrepreneurial equity partner supporting founders and management teams in different stages of development to grow and achieve a leading market position. Based in Karlsruhe, one of the largest technology clusters in Europe, LEA Partners has managed investments in numerous technology companies since 2002. Following the merger of PROCAD, keytech and ACATEC in May 2021 and that of TAIFUN, M-Soft and PinnCalc in October 2021, the establishment of a buy-and-build platform in the financial services sector, which already includes the b+m Group in addition to Base-Net Informatik AG, represents the next significant transaction for the LEA B2B Tech funds focused on software companies from the DACH region. For more information, please visit www.leapartners.de .
About Board Advisors
Board Advisors is a Management Consulting and M&A advisory firm founded in 2005 by Christoph Löslein and is today headquarted in Freiburg im Breisgau. Board Advisors currently has own operations in Berlin, Zurich, Sursee, Basel, Nice, Munich and Manchester and has a network of international cooperation partners.
Board Advisors has in-depth expertise in the health and technology sectors and has successfully completed numerous business development projects, buy- & sell-side transactions and fundraising mandates in recent years. For further information, please visit www.boardadvisors.de .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005562/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom